National Research Corp (NRCIA) is Trading Higher on Unusual Volume for December 21

Equities Staff |

National Research Corp (NRCIA) experienced unusually high volume on Dec. 21, as the stock gained 0.24% to a closing price of $16.74. The stock saw 76,170 shares trade hands over the course of the day on 199 trades. Given that the stock’s average daily volume over the last month has been 14,582 shares a day, this represents a pretty substantial spike over the norm.

National Research Corp has a P/B ratio of 4.7. It also has a P/E ratio of 25.8. The stock has traded between $17.00 and $10.72 over the last 52-weeks, its 50-day SMA is now $15.31, and its 200-day SMA $14.09.

National Research Corp implements surveys and performs analysis. Its subscription-based solutions provide actionable information and analysis to healthcare organizations.

Headquartered in Lincoln, NE, National Research Corp has 397 employees and is currently under the leadership of CEO Michael D. Hays.

For a complete fundamental analysis analysis of National Research Corp, check out’s Stock Valuation Analysis report for NRCIA. To see the latest independent stock recommendations from’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets

Initial State

Initial State is an Internet of Things (IoT) data analytics & data management platform company. We turn sensor and event data into information that matters by making it easy to…

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…